# A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

> **NCT06818812** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 30 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** INCB186748
- **DRUG:** Cetuximab
- **DRUG:** GEMNabP
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT06818812
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2027-03-27
- **Final completion:** 2027-03-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818812, "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06818812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*